The $2.49 billion cash purchase will give McKesson about 70% ownership of Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures).
Drug distributor McKesson signed a definitive agreement to purchase a controlling stake in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization formed by Florida Cancer Specialists & Research Institute (FCS).1
The $2.49 billion cash purchase will give McKesson about 70% ownership of Core Ventures, while physicians at the community oncology practice will retain their minority stake, according to a news release. Core Ventures oversees nonclinical administrative tasks, offering operational and advisory support services to FCS clinics throughout Florida. It was developed earlier in 2024 to partner with distributors in response to increasing drug shortages and prices.2
The $2.49 billion cash purchase will give McKesson about 70% ownership of Core Ventures | Image credit: Askar – stock.adobe.com
The transaction is pending regulatory approvals and other customary closing conditions, but once completed, Core Ventures will become part of McKesson’s Oncology platform, with financial results reported under the US Pharmaceutical segment.1 Additionally, FCS—which includes more than 250 physicians and 280 advanced practice providers across nearly 100 Florida locations—will remain independently owned and join McKesson's The US Oncology Network.
Brian Tyler, CEO of McKesson, called this agreement a “milestone” and “step forward” in McKesson’s work toward advancing community-based oncology care, which focuses on improving treatments and the overall patient experience while reducing costs.
“FCS and Core Ventures’ expertise and patient-first approach align with our commitment to accelerating clinical development, improving patient outcomes, and expanding access to quality cancer care in the community,” Tyler said. “We are also pleased to welcome Florida Cancer Specialists & Research Institute to The US Oncology Network, reinforcing our dedication to empowering community-based providers to independently thrive in today’s rapidly evolving healthcare landscape.”
Lucio N. Gordan, MD, president and managing physician at FCS, highlighted the importance of this deal for patients.
“Above all else, our patients are the true beneficiaries of this transaction, as we seek to drive meaningful outcomes and deliver sustained value with every interaction,” Gordan said. “Through the power of our combined operational expertise, we can bolster community oncology's role in increasing access to high-quality, affordable care.”
References
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More